(Total Views: 431)
Posted On: 11/25/2019 10:11:55 AM
Post# of 148891
"Intercept , looks like it could become first biopharma to get drug for NASH approved , although the results were somewhat mixed "
IMO results not very strong !!! about 11.2% response rate....
Obeticholic Acid clinical profile does suggest room for improvement.
Also with higher dose about 9% of patients stop treatment because of bad side effects .
All IMO
IMO results not very strong !!! about 11.2% response rate....
Obeticholic Acid clinical profile does suggest room for improvement.
Also with higher dose about 9% of patients stop treatment because of bad side effects .
All IMO
(2)
(0)Scroll down for more posts ▼
